Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 05, 2024

Outcomes of Treatment With Guselkumab in Patients With Pityriasis Rubra Pilaris

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial
JAMA Dermatol 2024 Apr 10;[EPub Ahead of Print], RC Velasco, C Shao, B Cutler, J Strunck, G Kent, PB Cassidy, K Choate, TM Greiling

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading